LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...

J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.

JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...

Eli Lilly and Company (LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B.

Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of Eli Lilly and ...

Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far ...

Leerink notes that Eli Lilly (LLY) lowered its Q4 total revenue guidance by 5% but issued initial 2025 revenue guidance 2% above consensus. Q4 ...

The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced lower-than-expected ...

Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue estimate stands at $13.95B. "While the U.S ...

BofA maintained LLY at Buy and a price target of $997.0, but said it was reviewing its estimates on the stock.

Lilly revised its revenue guidance down 5%, to $13.5 billion, missing consensus of $14 billion by $500 million. But the guidance still represents a 45% increase from the same quarter in 2023. Lilly ...